Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation

Drug Metabolism and Drug Interactions

Volumn 24, Issue 1, 2009, Pages 83-87

  Gallelli, Luca ^a   Ferraro, M ^b   Spagnuolo, V ^b   Rende, P ^a   Mauro, G F ^b   De Sarro, G ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b San Giovanni in Fiore Hospital   (Italy)

Author keywords

Creatine phosphokinase; CYP2C9; Rhabdomyolysis; Rosuvastatin; Woman

Indexed keywords

CARVEDILOL; CHOLESTEROL; CREATINE KINASE; CYTOCHROME P450 2C9; FUROSEMIDE; PRAVASTATIN; RANITIDINE; ROSUVASTATIN; TELMISARTAN; WARFARIN;

AGED; ARTICLE; ASTHENIA; BLOOD ANALYSIS; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE DURATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG REEXPOSURE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; LABORATORY TEST; LIVER FAILURE; LIVER SIZE; MUSCLE DISEASE; MUSCLE WEAKNESS; MYALGIA; RHABDOMYOLYSIS; SIDE EFFECT;

EID: 63449136622     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2009.24.1.83     Document Type: Article

References (14)

1. Pearson TA. The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. Am J Cardiol 2004; 94: 4F-8F.
2. Molokhia M, McKeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006. PLoS ONE 2008; 3: e2522.
3. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370: 1781-1790.
4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
5. Maroo BP, Lavie CJ, Milani RV. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike? Drugs Aging 2008; 25: 649-664.
6. McAfee AT, Ming EE, Walker AM. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. Pharmacoepidemiol Drug Saf 2004; 15: 444-453.
7. Alsheikh-Ali AA, Ambrose MS, Karas RH. The safety of rosuvastatin as used in common clinical practice. Circulation 2005; 111: 3051-3057.
8. Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis associated with pomegranate juice consumption. Am J Cardiol 2006; 98: 705-706.
9. Ireland JH, Eggert CH, Arendt CJ, Williams AW. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med 2005; 142: 949-950.
10. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 2005; 45: 927-934.
11. Jindal D, Tandon M, Sharma S, Pillai KK. Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects. Eur J Clin Pharmacol 2005; 61: 621-625.
12. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-710.
13. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-719.
14. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 2002; 287: 1690-1698.